Clincosm LogoSign in Get a demo

LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study

Sponsor
University of Alberta (Other)
Overall Status
Recruiting
CT.gov ID
NCT05645510
Collaborator
(none)
75
Enrollment
1
Location
18.2
Anticipated Duration (Months)
4.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

People with advanced chronic cancers are now living for many years as a result of new targeted anti-cancer treatments. Many of these treatments are quite new and people may take them for months, even years, as long as the treatments are helping. The purpose of this study is to help understand how to best support people receiving these treatments.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    75 participants
    Observational Model:
    Family-Based
    Time Perspective:
    Prospective
    Official Title:
    LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study
    Actual Study Start Date :
    Nov 24, 2022
    Anticipated Primary Completion Date :
    Nov 30, 2023
    Anticipated Study Completion Date :
    May 30, 2024

    Outcome Measures

    Primary Outcome Measures

    1. to learn the experiences of people and their caregivers living with incurable cancer [single interview]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 90 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion Criteria: taking chronic targeted anti-cancer agents -

    Exclusion Criteria:

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Edith Pituskin Edmonton Alberta Canada T6G 1C9

    Sponsors and Collaborators

    • University of Alberta

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Alberta
    ClinicalTrials.gov Identifier:
    NCT05645510
    Other Study ID Numbers:
    • HREBA.CC-22-0196
    First Posted:
    Dec 9, 2022
    Last Update Posted:
    Dec 9, 2022
    Last Verified:
    Nov 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Multiple Myeloma

    Study Results

    No Results Posted as of Dec 9, 2022